| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥4.1B | ¥4.1B | -0.1% |
| Operating Income | ¥-0.3B | ¥-0.5B | +101.5% |
| Ordinary Income | ¥-0.3B | ¥-0.5B | +93.5% |
| Net Income | ¥-0.3B | ¥-0.5B | +34.5% |
| ROE | -1.5% | -2.3% | - |
FY2026 Q1 results show revenue of 4.1B yen (YoY -0.1%), operating loss of -0.3B yen (loss improved +101.5% YoY), ordinary loss of -0.3B yen (loss improved +93.5%), and net loss of -0.3B yen (loss improved +34.5%). Revenue remained essentially flat year-over-year while operating loss narrowed from -0.5B yen to -0.3B yen, reflecting improved cost management despite ongoing profitability challenges. The company maintains a strong liquidity position with cash and deposits of 12.6B yen against total assets of 30.6B yen. High gross profit margin of 76.8% continues to be offset by selling, general and administrative expenses of 3.5B yen, representing 85.1% of revenue. Loss per share improved to -8.74 yen from -13.02 yen in the prior year quarter.
Revenue remained essentially flat at 4.1B yen, declining marginally by 0.1% year-over-year. Within the Medical Support segment, blood processing revenue increased 36.2% to 0.10B yen and raw material sales grew 43.4% to 0.09B yen, demonstrating strong growth in core medical operations. However, the D2C segment saw revenue decline 25.3% to 0.20B yen from 0.27B yen, primarily driven by mail-order sales dropping from 0.27B yen to 0.20B yen. The overseas business segment contributed 6.5M yen versus zero in the prior year, indicating early-stage international expansion efforts.
Operating loss improved significantly by 101.5% to -0.3B yen from -0.5B yen, driven by better expense absorption despite flat revenue. Gross profit of 3.1B yen maintained a healthy 76.8% margin, but selling, general and administrative expenses of 3.5B yen (85.1% of revenue) continued to exceed gross profit. The Medical Support segment loss improved to -11.4M yen from -24.7M yen, while D2C segment profit remained relatively stable at 85.8M yen compared to 80.3M yen. Unallocated corporate expenses of approximately 101M yen remained consistent year-over-year, contributing to overall operating losses.
The gap between ordinary loss and net loss was minimal, with ordinary loss at -0.3B yen incorporating interest expenses of 2.0M yen. No material extraordinary items impacted the quarter. Basic earnings per share of -8.74 yen improved from -13.02 yen, reflecting the narrowed net loss alongside an average share count of 3,530K shares. This represents a revenue flat/profit improvement pattern, where operational efficiency gains and segment mix improvements drove profitability progress despite top-line stagnation.
The Medical Support segment generated revenue of 200.4M yen with an operating loss of -11.4M yen, showing improvement from the prior year loss of -24.7M yen. This segment remains in investment mode with loss margin of -5.7%. The D2C segment produced revenue of 200.7M yen with operating profit of 85.8M yen, representing a healthy 42.8% operating margin and establishing it as the core profit-generating business. D2C revenue declined 25.6% year-over-year but maintained strong profitability, suggesting pricing power or cost discipline. The overseas business classified under "Other" contributed 6.5M yen in revenue with a loss of -6.9M yen, reflecting early-stage development expenses. After corporate expense allocation of approximately 101M yen, consolidated operating loss totaled -33.8M yen. The material margin differential between segments indicates D2C's role as the primary earnings driver, while Medical Support transitions toward profitability and overseas operations remain nascent.
[Profitability] ROE was -1.5% compared to -2.5% in the prior year, showing improvement but remaining negative due to net losses. Operating margin stood at -8.1%, improved from -12.2% year-over-year by 4.1 percentage points, reflecting better expense management. Gross profit margin of 76.8% demonstrates strong pricing power and favorable product mix, though undermined by SG&A expenses at 85.1% of revenue. Net profit margin of -7.4% improved from -11.3% in the prior period. [Cash Quality] Cash and deposits of 12.6B yen provide coverage of 2.0 times short-term liabilities of 6.2B yen, indicating robust liquidity buffers. Current assets of 16.7B yen against current liabilities of 6.2B yen yield a current ratio of 271.7%. [Investment Efficiency] Asset turnover of 0.133 remains low, reflecting the capital-intensive nature and intangible asset base. Inventory of 1.0B yen represents 404 days of inventory outstanding, signaling slow turnover and potential working capital optimization opportunities. Receivables of 2.5B yen convert at 228 days sales outstanding, indicating extended collection periods. [Financial Health] Equity ratio of 67.6% demonstrates a conservative capital structure with total equity of 20.7B yen against total assets of 30.6B yen. Long-term loans of 3.0B yen and short-term borrowings of 1.9B yen result in total interest-bearing debt of 4.9B yen, yielding a debt-to-equity ratio of 0.24 times. Goodwill of 9.8B yen and total intangible assets of 9.8B yen represent 32.0% of total assets, creating elevated impairment monitoring requirements.
Cash and deposits decreased to 12.6B yen from 13.0B yen in the prior year quarter, declining 0.4B yen while maintaining substantial liquidity coverage. The balance sheet indicates working capital absorption through increased inventory of 1.0B yen and receivables of 2.5B yen, though partially offset by increased payables of 0.1B yen. Total current assets of 16.7B yen against current liabilities of 6.2B yen provide a current ratio of 2.72 times and quick ratio of 2.55 times, confirming adequate near-term solvency. Interest-bearing debt totaling 4.9B yen is covered 2.6 times by cash balances, indicating low refinancing pressure. The equity base of 20.7B yen slightly declined from 20.9B yen, consistent with accumulated losses during the quarter. Net working capital expansion reflects operational cash consumption despite loss reduction, suggesting continued investment in inventory and extended customer payment terms that may pressure liquidity if sales acceleration does not materialize.
Ordinary loss of -0.3B yen compared to operating loss of -0.3B yen shows minimal non-operating impact, with net non-operating expense of approximately 2.0M yen consisting primarily of interest expense. Non-operating items represent less than 1% of revenue, indicating core operations drive the loss position rather than financial costs. Interest expense of 2.0M yen on total interest-bearing debt of 4.9B yen implies an effective borrowing cost of approximately 1.6% on an annualized basis, which is manageable. The absence of material equity method gains, extraordinary gains, or non-recurring items suggests the reported loss reflects normalized operational performance. The high gross margin of 76.8% provides evidence of sustainable business model fundamentals, with profitability challenges stemming from scale-related overhead rather than product economics. However, the extended receivables collection period of 228 days and inventory holding period of 404 days raise concerns about cash conversion efficiency, as operating cash generation capability cannot be directly verified without quarterly cash flow statement disclosure. The quality of earnings would improve materially upon confirmation that operating cash flow approaches or exceeds net income levels once profitability is achieved.
Progress against full-year guidance shows Q1 revenue of 4.1B yen representing 17.5% of the 23.4B yen annual forecast, below the standard 25% quarterly run rate by 7.5 percentage points. Operating income progress is not meaningful given Q1 loss of -0.3B yen against full-year guidance of 3.0B yen profit, indicating substantial back-end loading with losses expected to reverse in subsequent quarters. Ordinary income similarly shows -0.3B yen Q1 loss against 2.9B yen full-year guidance. The company forecasts full-year EPS of 52.44 yen and maintains zero dividend policy with no change from initial guidance. The below-standard Q1 progress rate of 17.5% on revenue implies management expects 19.6% year-over-year growth to accelerate significantly, requiring average quarterly revenue of approximately 6.4B yen across the remaining three quarters compared to Q1's 4.1B yen. This suggests either pronounced seasonality in the Medical Support and D2C segments or anticipated new business contributions from overseas operations. Achievement of the 3.0B yen operating income target from a -0.3B yen Q1 starting point necessitates quarterly operating profit averaging approximately 1.1B yen in Q2 through Q4, representing an operational inflection that would reverse current loss-making structure through revenue scale and fixed cost leverage.
Revenue concentration risk exists with dependence on two primary segments, Medical Support and D2C, where D2C mail-order revenue declined 25.3% year-over-year to 200M yen from 268M yen, creating vulnerability to consumer demand fluctuations and digital commerce trends. The SG&A expense structure at 3.5B yen (85.1% of revenue) exceeds gross profit of 3.1B yen, creating operating leverage sensitivity where revenue shortfalls or margin compression directly translate to magnified loss expansion given the fixed cost burden of approximately 101M yen in unallocated corporate expenses. Asset impairment exposure is material with goodwill of 9.8B yen and total intangible assets representing 32.0% of total assets at 30.6B yen, requiring sustained profitability achievement to support carrying values and avoid potential impairment charges that would directly reduce equity currently at 20.7B yen.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating Margin -8.1% significantly underperforms the industry median of 6.8% (IQR: 2.9%-9.0%) by 14.9 percentage points, placing the company in the bottom quartile. Net Profit Margin of -7.4% also trails the industry median of 5.9% (IQR: 3.3%-7.7%), consistent with loss-making operations. ROE of -1.5% compares unfavorably to the industry median of 3.1% (IQR: 2.0%-4.9%).
Financial Health: Equity Ratio of 67.6% substantially exceeds the industry median of 43.9% (IQR: 28.4%-50.7%), ranking in the top quartile and demonstrating conservative capitalization. Current Ratio of 2.72x surpasses the industry median of 1.87x (IQR: 1.86x-2.23x), indicating superior short-term liquidity positioning.
Efficiency: Asset Turnover of 0.133 falls below the industry median of 0.17 (IQR: 0.16-0.23), reflecting lower capital productivity. Inventory Turnover of 404 days is notably worse than the industry median of 498 days, though within the broader range. Receivables Turnover at 228 days aligns closely with the industry median of 269 days (IQR: 168-456 days).
Growth: Revenue Growth of -0.1% significantly lags the industry median of 13.2% (IQR: 2.5%-28.5%), positioning the company in the bottom decile for top-line expansion.
The company exhibits a defensive financial profile with strong balance sheet metrics but faces profitability and growth challenges relative to manufacturing industry peers. High equity ratio and liquidity provide downside protection while operational turnaround execution remains critical.
※ Industry: Manufacturing (8 companies), Comparison: 2025-Q1 periods, Source: Proprietary analysis
The company demonstrates a bifurcated business model where strong gross margins of 76.8% and healthy D2C segment profitability (42.8% operating margin) are offset by elevated corporate overhead and Medical Support segment losses, creating a structural profitability challenge that requires either revenue scale expansion or cost rationalization to achieve sustainable earnings. The Medical Support segment showed improving loss trajectory from -24.7M yen to -11.4M yen year-over-year, suggesting progression toward breakeven that could materially improve consolidated results if continued, particularly given growth in blood processing revenue (+36.2%) and raw material sales (+43.4%) within this segment. The substantial gap between Q1 performance (revenue at 17.5% of full-year guidance, operating loss of -0.3B yen) and full-year profitability guidance (3.0B yen operating income, 23.4B yen revenue) represents a critical execution risk and monitoring point, with management credibility dependent on visible improvement in Q2 and Q3 results demonstrating the anticipated operational inflection and seasonal revenue acceleration.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.